Obesity, Metabolic Syndrome, and Obesity Paradox in Heart Failure: A Critical Evaluation DOI

Vince Catalfamo,

Austin W. Tutor,

Adrienne Koos

et al.

Current Heart Failure Reports, Journal Year: 2024, Volume and Issue: 22(1)

Published: Nov. 15, 2024

Language: Английский

Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions DOI
Naveed Sattar, Matthew M.Y. Lee

The Lancet Diabetes & Endocrinology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

3
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) DOI Creative Commons
Subodh Verma, Helen M. Colhoun, Dror Dicker

et al.

Journal of the American College of Cardiology, Journal Year: 2024, Volume and Issue: 84(17), P. 1678 - 1682

Published: Aug. 30, 2024

Language: Английский

Citations

9
Responder Analyses Can Be Misleading DOI

Mary Southworth,

Mitchell A. Psotka,

Jordan E Pomeroy

et al.

Journal of the American College of Cardiology, Journal Year: 2025, Volume and Issue: 85(2), P. 196 - 198

Published: Jan. 1, 2025

Language: Английский

Citations

1
Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults DOI Creative Commons
Ashkan Hashemi, Min Ji Kwak, Parag Goyal

et al.

Drugs & Aging, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 18, 2025

Language: Английский

Citations

1
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction DOI Creative Commons
Misato Chimura, Xiaowen Wang, Pardeep S. Jhund

et al.

JAMA Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 17, 2024

Importance Sex is associated with the clinical presentation, outcomes, and response to treatment in patients heart failure (HF). However, little known about safety efficacy of finerenone according sex. Objective To estimate compared placebo both women men. Design, Setting, Participants Prespecified analyses were conducted phase 3 randomized trial Finerenone Trial Investigate Efficacy Safety Superior Placebo Patients Heart Failure (FINEARTS-HF). The was across 653 sites 37 countries. adults aged 40 years older symptomatic HF left ventricular ejection fraction (LVEF) 40% or greater between September 2020 January 2023. Intervention (titrated 20 mg mg) placebo. Main Outcomes Measures primary outcome a composite cardiovascular death total (first recurrent) events (unplanned hospitalizations urgent visits). Results A 6001 FINEARTS-HF, whom 2732 (45.5%), mean (SD) age 73.6 (9.1) years. Women had higher rates any obesity, LVEF (54.6 [7.6%] vs 50.9 [7.6] for men), lower estimated glomerular filtration rate than men (59.7 [19.1] 64.1 [20.0] men; P<.001) , worse New York Association functional class, Kansas City Cardiomyopathy Questionnaire-Total Symptom Scores (KCCQ-TSS) (mean [SD] 62.3 [24.0] 71.0 [23.1]). incident slightly (15.7; 95% CI, 14.3-17.3) (16.8; 15.4-18.3) per 100 person-years. Compared placebo, reduced risk end point similarly men: ratio 0.78 (95% 0.65-0.95) 0.88 0.74-1.04) ( P = .41 interaction). Consistent effects observed components all-cause mortality. increase (improvement) KCCQ-TSS from baseline 12 months finerenone, regardless sex .73 similar tolerability Conclusions Relevance In mildly preserved fraction. Registration ClinicalTrials.gov Identifier: NCT04435626

Language: Английский

Citations

4
Do weight loss interventions challenge the obesity paradox in heart failure? DOI
Salva R. Yurista, Robert A. Eder, W. Scott Butsch

et al.

Trends in Endocrinology and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Underpinnings of Heart Failure With Preserved Ejection Fraction in Women - From Prevention to Improving Function. A Co-publication With the American Journal of Preventive Cardiology and the Journal of Cardiac Failure DOI

Archanna Radakrishnan,

Shashank Agrawal, Neha Singh

et al.

Journal of Cardiac Failure, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Underpinnings of heart failure with preserved ejection fraction in women - From prevention to improving function. A co-publication with the American Journal of Preventive Cardiology and the Journal of Cardiac Failure DOI Creative Commons

Archanna Radakrishnan,

Saloni Agrawal,

Nausheen Singh

et al.

American Journal of Preventive Cardiology, Journal Year: 2025, Volume and Issue: unknown, P. 100928 - 100928

Published: Feb. 1, 2025

Language: Английский

Citations

0
Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide DOI Creative Commons

Celestine I. Odigwe,

Rajasekhar Mulyala,

H. A. Malik

et al.

American Heart Journal Plus Cardiology Research and Practice, Journal Year: 2025, Volume and Issue: 52, P. 100518 - 100518

Published: March 1, 2025

Semaglutide, a GLP-1 receptor agonist, has emerged as promising agent in cardiovascular disease management, particularly for patients with obesity and diabetes. Recent studies have demonstrated significant benefits of Semaglutide beyond glycemic control, including reduced major adverse events (MACE), improvements heart failure symptoms, weight reduction. Notably, the STEP-HFpEF trial highlighted improved exercise capacity reduction NT-proBNP levels, offering novel therapeutic pathway management. Additionally, shown anti-inflammatory effects, reducing C-reactive protein (CRP) tumor necrosis factor-alpha (TNF-α), thereby mitigating atherosclerotic risks. Moreover, SELECT Semaglutide's non-diabetic, obese patients, suggesting that its effects extend loss. These findings represent potential paradigm shift risk although access affordability remain key challenges.

Language: Английский

Citations

0
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment DOI Creative Commons

Richard Salvador,

Carla Moutinho, Carla Silva

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(3), P. 399 - 399

Published: March 12, 2025

This review addresses the role of semaglutide (SMG), a GLP-1 receptor agonist, in treatment obesity and its related comorbidities. Originally developed for type 2 diabetes (DM2), SMG has shown significant efficacy weight reduction, with superior results compared to other treatments same class. Its effects include appetite suppression, increased satiety, improvements cardiovascular, renal, metabolic parameters. Studies such as SUSTAIN, PIONEER, STEP highlight superiority agonists anti-obesity drugs. The oral formulation showed promising initial results, higher doses (50 mg) showing losses comparable those subcutaneous administration. Despite benefits, there are challenges, regain after cessation treatment, gastrointestinal adverse effects, variability response. Future studies should explore strategies mitigate these identify predictive factors efficacy, expand therapeutic indications conditions insulin resistance. constant innovation this class drugs reinforces potential transform protocols chronic weight-related diseases.

Language: Английский

Citations

0